CELSET Launches SOLTOX Botulinum Toxin Brand for International Markets
CELSET, a South Korean biotechnology company, launched its SOLTOX botulinum toxin type A brand for international markets.
Related stories
Starbucks Reports Fourth-Quarter and Full-Year Fiscal 2026 Results
Starbucks reported results for its 13-week fiscal fourth quarter and 52-week fiscal year ended September 27, 2026.
M impact | EQUITY | Oct 29, 2026, 08:22 PM UTC
SkyWest Q3 2026 Results Hit by Higher Fuel Costs in Prorate Business
SkyWest said higher fuel cost per gallon in its prorate business negatively impacted Q3 2026 financial results versus Q3 2025 and Q2 2026.
M impact | EQUITY | Oct 29, 2026, 08:08 PM UTC
Workhorse Secures $10 Million RHAELM Contract to Build TerraPod Reference Unit
Workhorse signed a $10 million RHAELM contract to build a TerraPod reference unit.
M impact | EQUITY | Oct 29, 2026, 08:08 PM UTC
Intel Shares Fall 17.08% to $76.35 After Results and Outlook
M impact | EQUITY | Oct 29, 2026, 08:08 PM UTC
PTC Therapeutics Swings to Q3 Net Loss of $51.69 Million
PTC Therapeutics reported a net loss of $51.69 million for Q3 2026, compared with a profit a year earlier.
M impact | EQUITY | Oct 29, 2026, 08:08 PM UTC
Forrester Research Reports Third-Quarter Revenue of $107,000
M impact | EQUITY | Oct 29, 2026, 08:07 PM UTC